Merck & Company Receives a Sell from Jefferies

By Carrie Williams

Jefferies analyst Jeffrey Holford reiterated a Sell rating on Merck & Company (NYSE: MRK) on March 9 and set a price target of $52. The company’s shares closed yesterday at $64.15.

According to, Holford is a 5-star analyst with an average return of 8.0% and a 74.4% success rate. Holford covers the Healthcare sector, focusing on stocks such as Parnell Pharmaceuticals, Johnson & Johnson, and Sanofi-Aventis Sa.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $65.50.

The company has a one year high of $66.80 and a one year low of $51.33. Currently, Merck & Company has an average volume of 10.7M.

Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. Last month, Patricia Russo, a Director at MRK sold 5,000 shares for a total of $322,100.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.